Pharmacyclics, Inc. (NASDAQ: PCYC) is one of the best ways to play the hematology cancer drug market as its Ibrutinib is expected to transform the treatment of many blood cancers.
Pharmacyclics' lead drug Ibrutinib is under FDA review for second line chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is in pivotal trials for many other indications.
The company is developing Ibrutinib along with Johnson and Johnson (NYSE:JNJ). Ibrutinib is a Bruton's Tyrosine Kinase (BTK) inhibitor, which leads to death of cancerous cells.
The compound is most advanced in CLL and MCL where it is under FDA review in second-line treatment of these patients (Relapsed Refractory or R/R).
Due to its promising activity in R/R CLL, R/R MCL, the FDA has granted "BreakThrough" designation to Ibrutinib in these three indications. Pharmacyclics and JNJ filed for accelerated approval in R/R CLL and R/R MCL in the second quarter of 2013 based on Phase II data, and the FDA's decision is expected by early'14. The potential PDUFA goal date in late February 2014.
Hot Up And Coming Stocks To Buy Right Now: IDEXX Laboratories Inc (IDXX)
IDEXX Laboratories, Inc., incorporated in 1983, develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company operates through three segments: diagnostic and information technology-based products and services for the veterinary market, which it refers to as the Companion Animal Group (CAG), water quality products (Water) and products for livestock and poultry health, which it refer to as Livestock and Poultry Diagnostics (LPD). It also operates two smaller segments that consist of products for milk quality and safety (Dairy) and products for the human point-of-care medical diagnostics market (OPTI Medical). In November 2011, the Company acquired the research and diagnostic laboratory (RADIL) business of the College of Veterinary Medicine from the University of Missouri. In August 2013, IDEXX Laboratories, Inc. announced that it has acquired Madasa do Brasil Ltda.
The Company sells a range of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its primary products and services are point-of-care veterinary diagnostic products, consisting of instruments and consumables and rapid assays; veterinary reference laboratory diagnostic and consulting services used by veterinarians; diagnostic and health-monitoring products for livestock and poultry; products that test water for certain microbiological contaminants; practice management systems and services and digital radiography systems used by veterinarians; products that test milk for antibiotic residues and other contaminants, and point-of-care electrolytes and blood gas analyzers used in the human point-of-care medical diagnostics market.
Companion Animal Group
The Company markets a range of in-clinic laboratory analyzers for use in providing reference laboratory quality diagnostic results in companion animal veterinary practices, which it refers ! to as the IDEXX VetLab suite of analyzers. The Company sells two chemistry analyzers, the Catalyst Dx Chemistry Analyzer and the VetTest Chemistry Analyzer, that are used by veterinarians to measure levels of certain enzymes and other substances in blood or urine for monitoring health status and assistance in diagnosing physiologic conditions. Both instruments use consumables manufactured for IDEXX by Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, based on Ortho�� dry slide technology (Catalyst Dx slides, VetTest slides or slides). In addition, the Catalyst Dx analyzer also uses dry slide electrolyte consumables manufactured by IDEXX at OPTI Medical Systems, one of its wholly owned subsidiaries. Blood tests commonly run on these analyzers include glucose, alkaline phosphatase, alanine aminotransferase (ALT), albumin, creatinine, blood urea nitrogen (BUN), and total protein. Tests are sold individually and in prepackaged panels. Both analyzers also run a urine test called urine protein:creatinine ratio, which assists in the detection of early renal disease.
The Catalyst Dx analyzer is the Company�� chemistry analyzer. The Catalyst Dx analyzer allows a veterinarian to run multiple patient samples simultaneously; to run different sample types, including whole blood, plasma, serum and urine; to perform 28 different chemistry and electrolyte tests; and to automatically calculate other parameters and ratios important to blood chemistry analysis. Its VetLyte Electrolyte Analyzer measures three electrolytes-sodium, potassium and chloride-to aid in evaluating acid-base and electrolyte balances and assessing plasma hydration. Its VetStat Electrolyte and Blood Gas Analyzer measures electrolytes, blood gases, glucose and ionized calcium, and calculates other parameters, such as base excess and anion gap. These measurements aid veterinarians in diagnosing various disease states, evaluating fluid therapy choices and measuring respiratory function. The VetStat analyzer ru! ns single! -use disposable cassettes that contain various configurations of analytes. The VetStat analyzer and its cassettes are manufactured by OPTI Medical Systems.
The Company sells three hematology analyzers that assess the cellular components of blood, including red blood cells, white blood cells and platelets (also called a complete blood count (CBC)). These analyzers include the ProCyte Dx Hematology Analyzer, which uses laser-flow cytometry, optical fluorescence and laminar-flow impedance in its analysis; the LaserCyte Hematology Analyzer, which uses laser-flow cytometry technology in its analysis, and the IDEXX VetAutoread Hematology Analyzer. It also sells the Coag Dx Analyzer, which permits the detection and diagnosis of blood clotting disorders. The ProCyte Dx analyzer provides validated results for five species (canine, feline, equine, bovine and ferret) for up to 24 different blood parameters, providing a more complete picture of each patient�� health.
The SNAPshot Dx analyzer provides quantitative measurements of total thyroxine (T4), cortisol and bile acids to assist in the evaluation of thyroid, adrenal and liver function. The SNAPshot Dx analyzer also reads, interprets and records the results of many IDEXX rapid assay SNAP tests, including its canine SNAP 4Dx test, feline SNAP FIV/FeLV Combo test, canine SNAP cPL test, feline SNAP fPL test, SNAP Feline Triple test and canine SNAP Heartworm RT test. The IDEXX VetLab UA Analyzer provides chemical urinalysis and is validated specifically for veterinary use. The IDEXX VetLab Station (IVLS) connects and integrates the diagnostic information from all the IDEXX VetLab equipment and thus provides reference laboratory information management system capability. It sells the IVLS as an integral component of the Catalyst Dx, LaserCyte and ProCyte Dx analyzers and also as a standalone hardware platform.
The IVLS includes a user interface to input patient information, connect with a practice management system and send i! nformatio! n to run the individual analyzers. IVLS also generates one integrated patient report incorporating all of the lab work generated by the IDEXX VetLab suite; stores, retrieves and analyzes historical patient diagnostics data, including SNAP test results; and sends and receives information from practice management systems, including the IDEXX Cornerstone system, as well as a variety of third-party systems. It sells a range of single-use, handheld test kits under the SNAP name. In addition to its single-use tests, it sells a range of microwell-based test kits under the PetChek name for canine heartworm, FIV and FeLV.
The Company offers commercial reference laboratory diagnostic and consulting services to veterinarians in the United States, Canada, Europe, Australia, Japan, South Africa, China and South Korea and to bioresearch customers in the United States and Europe. The Company provides specialized veterinary consultation, telemedicine and advisory services, including radiology, cardiology, internal medicine and ultrasound consulting. It develops, markets and sells practice management systems, including hardware and software, and services that run certain functions of veterinary clinics, including managing patient electronic health records, scheduling (including boarding and grooming), reminders, billing and inventory management.
The Company markets and sells two digital radiography systems for use in the small animal veterinary hospital: the IDEXX-DR 1417 and the IDEXX I-Vision CR. Its digital radiography systems use IDEXX-PACS and IDEXX EquiView PACS picture archiving and communication system (PACS) software for the viewing, manipulation, management, storage and retrieval of the digital images generated by the digital capture plate. In September 2011, the Company launched IDEXX I-Vision Mobile, an application that allows veterinarians with the IDEXX-DR 1417 and IDEXX I-Vision CR systems, as well as its digital radiography systems, to request, view and send images using an iPa! d or an A! ndroid mobile tablet. This application integrates with its IDEXX-PACS software.
Water
The Company offers a range of products used in the detection and quantification of various microbiological parameters in water. Its principal products are the Colilert, Colilert-18 and Colisure tests, which simultaneously detect the presence of total coliforms and E. coli in water. These organisms are used as indicators of microbial contamination in water. These products utilize indicator-nutrients that produce a change in color or fluorescence when metabolized by target microbes in the sample. Its water tests are used by government laboratories, water utilities and private certified laboratories to test drinking water. The tests also are used in evaluating water used in production processes (for example, in beverage and pharmaceutical applications) and in evaluating bottled water, recreational water, waste water and water from private wells.
Livestock and Poultry Diagnostics
The Company sells diagnostic tests and related instrumentation that are used to detect a range of diseases and to monitor health status in livestock and poultry. Its livestock and poultry diagnostic products are purchased by government and private laboratories that provide testing services to cattle, swine and poultry veterinarians and producers. Its principal products include tests for Bovine Viral Diarrhea Virus (BVDV), Porcine Reproductive and Respiratory Syndrome (PRRS) and Bovine Spongiform Encephalopathy (BSE or mad cow disease). BVDV is a common and contagious viral infection that suppresses the immune system, making the animal susceptible to a host of other infections, impacting beef and dairy production yields as a result. PRRS is a contagious virus causing reproductive problems and respiratory diseases. BSE is a fatal neurodegenerative disease in cattle that causes a spongy degeneration in the brain and spinal cord.
Other
The principal products in the Company�! � Dairy ! business are its SNAP tests used to detect antibiotic drug-residue in milk. Its primary product line for detecting antibiotic residue in milk is SNAP Beta-Lactam, which detects penicillin, amoxicillin, ceftiofur and cephaphirin residues, followed by SNAPduo Beta-Tetra, which detects certain tetracycline antibiotic residues in addition to those detected by the SNAP Beta Lactam test kits. It also sells SNAP tests for the detection of certain other contaminants in milk, such as chemical melamine and Alfatoxin M1.
The Company sells OPTI point-of-care analyzers and related consumables for use in human medical hospitals and clinics to measure electrolytes, blood gases, acid-base balance, glucose, lactate, BUN and ionized calcium, and to calculate other parameters, such as base excess and anion gap. These analyzers are used primarily in emergency rooms, operating rooms, cardiac monitoring areas and other locations where time-critical diagnostic testing is performed within the hospital setting. The OPTI CCA and OPTI Touch Electrolyte and Blood Gas Analyzers run single-use disposable cassettes that contain various configurations of analytes; the OPTI R Analyzer runs reusable cassettes in various analyte configurations; and the OPTI LION Stat Electrolyte Analyzer runs single-use electrolyte cassettes. OPTI Medical Systems also manufactures its VetStat analyzer and provides the electrolyte module and dry slide reagents that make up the electrolyte testing functionality of the Catalyst Dx analyzer.
The Company competes with VCA Antech, Inc., Abaxis, Inc., Butler, Radiometer A/S, Siemens Medical Solutions Diagnostics, Instrumentation Laboratory, Abbott Diagnostics and Roche Diagnostics.
Advisors' Opinion:- [By Sean Williams]
Ignore this trend at your own risk
If you choose to do nothing, then you're playing right into the hands of pharmaceutical giants like Zoetis (NYSE: ZTS ) , Merck (NYSE: MRK ) , and IDEXX Laboratories (NASDAQ: IDXX ) , which are counting on your indifference to drive their profits.
5 Best Promising Stocks To Buy For 2014: Basilea Pharmaceutica AG (BSLN)
Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company�� anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company�� subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd. Advisors' Opinion:- [By Corinne Gretler]
Basilea Pharmaceutica AG (BSLN) increased 2.1 percent to 107.10 francs. The Swiss drug developer said the U.S. Food and Drug Administration granted orphan-drug designation to its isavuconazole for the treatment of zygomycosis, a life-threatening fungal infection.
5 Best Promising Stocks To Buy For 2014: SEI Investments Co (SEIC)
SEI Investments Company (SEI), incorporated on November 18, 1968, is a global provider of investment processing, investment management, and investment operations solutions. The Company helps corporations, financial institutions, financial advisors, and ultra-high-net-worth families create and manage wealth by providing comprehensive, investment and investment-business solutions. The Company�� business segments include Private Banks , Investment Advisors , Institutional Investors, Investment Managers and Investments in New Businesses.
The Company�� wealth management business solutions include investment processing outsourcing solutions for banks, trust companies, independent wealth advisers, and investment managers; investment management programs for affluent individual investors and for institutional investors, including retirement plan sponsors, and not-for-profit organizations; and investment operations outsourcing solutions for investment management firms, banks and investment companies that sponsor and distribute mutual funds, hedge funds, and alternative investments.
The Company�� Investment processing solutions consist of application and business process outsourcing services, professional services, and transaction-based services. It delivers these solutions to providers of institutional and private client wealth management services, including banks, trust companies, independent wealth advisers, and other financial services firms. It also delivers these solutions, combined with its investment management programs, to investment advisory firms and other financial services firms that provide wealth management services to their advisory clients. The Company�� investment processing solutions are enabled through two platforms, TRUST 3000 and the Global Wealth Platform (GWP).
Investment management programs consists of money market, fixed-income and equity mutual funds and other collective investment products, alternative investment portfolios, and separate! ly managed accounts. The Company serves as the sponsor, administrator and investment advisor for many of these products. It distributes these programs primarily through investment advisory firms, including investment advisors and banks, and directly to institutional or individual investors. Investment operations outsourcing solutions consist of accounting and administration services, and distribution support services. It delivers these solutions to investment management firms that offer traditional and alternative products.
Private Banks
The Private Banks segment delivers a comprehensive outsourcing solution integrating investment processing services, investment management and distribution programs, and business to banks and trust institutions worldwide, independent wealth advisers and other wealth managers located in the United Kingdom, and financial advisors in Canada. The Company owns, maintains and operates the software applications and information processing facilities for all of its investment processing solutions.
Private banks and other trust organizations who utilizes its TRUST 3000 application solution outsource investment processing technology software and computer processing, but retain responsibility for investment operations, client administration, and investment management. These clients operate its TRUST 3000 application remotely while fully supported by its data center using dedicated telecommunications networks.
Investment Advisors
The Investment Advisors segment offers wealth management solutions to registered investment advisors, many of whom are affiliated with or are registered as independent broker-dealers, financial planners, and life insurance agents located throughout the United States. These wealth management solutions include the Company�� investment management programs and back-office investment processing outsourcing services and are usually offered on a bundled basis. Its solutions helps investment ! advisors ! reduce risk, improve quality, and gain operational efficiency to devote more of their resources to servicing their clients and acquiring new clients. Advisors are responsible for the investor relationship which includes creating financial plans, implementing investment strategies and educating and servicing their customers. Advisors may customize portfolios to include separate account managers provided through its programs as well as SEI-sponsored mutual funds.
Institutional Investors
The Institutional Investors segment offers investment management programs and administrative outsourcing solutions for retirement plan sponsors, hospitals, and not-for-profit organizations globally. Clients can outsource their investment management needs and the administration for defined benefit plans, defined contribution plans, endowments, foundations, and other balance sheet assets. The fiduciary management outsourcing program provides a strategic platform integrating the Manager-of-Managers investment process, plan administration services, and consulting services. Plan administration services include trustee, custodial, benefit payment services, record-keeping services, and donor administration. Consulting services include actuarial services, asset liability modeling, and the customization of an asset allocation.
Investment Managers
The Investment Managers segment provides a platform of comprehensive investment operations outsourcing solutions to investment managers globally. This array of front-, middle- and back-office investment processing services integrates industry tools and technology to support a manager's diverse business needs across multiple product types and structures, investment strategies and asset classes. The Company provides outsourcing services including fund and investment accounting, administration, reconciliation, investor servicing and client reporting. It also provides comprehensive solutions to managers focused on alternative investments who ! manage he! dge funds, funds of hedge funds, private equity funds, real estate and infrastructure funds, across registered, partnership and separate account structures domiciled in the United States and overseas.
Investments in New Businesses
The Investments in New Businesses segment represents other business ventures or research and development activities intended to expand its solutions to new or existing markets including ultra-high-net-worth families who reside in the United States. This segment includes the costs associated with business development in the Middle East through its Dubai office and the development of a Internet-based investment management application. The family wealth management solution offers flexible family-office type services through a personalized solution while utilizing the Manager-of-Managers investment process.
The Company competes with Fidelity National Information Services, Inc., SunGard Data Systems Inc., State Street Corporation, Fi-Tek LLC, Charles Schwab & Co., Inc.,Fidelity Investments,Pershing LLC, FNZ UK Ltd., Temenos Group AG, Avaloq, TD Direct Investing (Europe) Ltd.,Russell Investment Group,Franklin Templeton Investments,AssetMark Investment Services Inc., Brinker Capital, EnvestNet Asset Management, Inc., Lockwood Advisors, Inc., Charles Schwab & Co., Inc., Northern Trust Corporation, State Street and BNY Mellon.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SEI Investments (Nasdaq: SEIC ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on SEI Investments (Nasdaq: SEIC ) , whose recent revenue and earnings are plotted below. - [By Marc Bastow]
Investment and fund processing and management company SEI Investments (SEIC) raised its semi-annual dividend 10% 22 cents per share, payable on Jan. 10 to shareholders of record as of Dec. 23.
SEIC Dividend Yield: 1.33%
5 Best Promising Stocks To Buy For 2014: Australian Dollar(AU)
AngloGold Ashanti Limited primarily engages in the exploration and production of gold. It also produces silver, uranium oxide, and sulfuric acid. The company conducts gold-mining operations in South Africa; continental Africa, including Ghana, Guinea, Mali, Namibia, and Tanzania; Australia; and the Americas, which include Argentina, Brazil, and the United States. It also has mining or exploration operations in the Democratic Republic of the Congo, Guinea, and Colombia. As of December 31, 2010, the company had proved and probable gold reserves of 71.2 million ounces. The company has a strategic alliance with Thani Dubai Mining Limited to explore, develop, and operate mines across the Middle East and parts of North Africa. AngloGold Ashanti Limited, formerly known as Vaal Reefs Exploration and Mining Company Limited, was founded in 1944 and is headquartered in Johannesburg, South Africa.
Advisors' Opinion:- [By Dan Caplinger]
One way Yamana has kept its competitive cost advantage is through extensive sales of base-metal byproducts like copper and zinc, as both it and fellow low-cost rival Goldcorp (NYSE: GG ) benefit from utilizing those secondary metals to offset the cost of their gold production. Peers Gold Fields (NYSE: GFI ) and AngloGold Ashanti (NYSE: AU ) , on the other hand, face much higher costs in part because of their exposure to South Africa and its unstable labor market.
- [By Dan Caplinger]
But even bigger damage came from gold-mining stocks. AngloGold Ashanti (NYSE: AU ) has lost almost 60% of its value in 2013, with the drop in gold prices having an outsized impact on the gold miner's prospects. AngloGold has also suffered from investors moving away from emerging markets like South Africa in favor of U.S. stocks, as fears of the Federal Reserve's exit from its quantitative easing program have reduced overall risk tolerance among many investors.
- [By Sally Jones]
Anglogold Ashanti Limited (AU)
Down 65% over 12 months, Anglogold Ashanti Limited has a market cap of $4.85 billion, and trades with a P/E of 8.10.
No comments:
Post a Comment